

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



三生制药
3SBIO INC.

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1530)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.* 三生國健藥業（上海）股份有限公司 (Stock Code: 688336), an indirect non-wholly owned subsidiary of 3SBio Inc. (the “**Company**”), has published an announcement on the website of the Shanghai Stock Exchange in respect of its product Yisaipu (益賽普) on 21 October 2019. For details, please refer to the information disclosure page of the website of the Shanghai Stock Exchange (<http://star.sse.com.cn/disclosure/listannouncement/>).

By order of the Board
3SBio Inc.
Dr. LOU Jing
Chairman

Shenyang, the PRC
21 October 2020

As at the date of this announcement, the directors of the Company are Dr. LOU Jing and Ms. SU Dongmei as executive directors; Mr. HUANG Bin and Mr. TANG Ke as non-executive directors; and Mr. PU Tianruo, Mr. David Ross PARKINSON and Dr. WONG Lap Yan as independent non-executive directors.

* *for identification purposes only*